Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir-Reference-Cited by-同舟云学术

Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir

Published:2022-08-04 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Dai Eric Y.,Lee Kannon A.,Nathanson Audrey B.,Leonelli Ariana T.,Petros Brittany A.^ORCID,Brock-Fisher Taylor,Dobbins Sabrina T.,MacInnis Bronwyn L.,Capone Amelia,Littlehale Nancy,Boucau Julie,Marino Caitlin,Barczak Amy K.,Sabeti Pardis C.,Springer Michael^ORCID,Stephenson Kathryn E.^ORCID

Abstract

ABSTRACTWe measured viral kinetics of SARS-CoV-2 Omicron infection in 36 mRNA-vaccinated individuals, 11 of whom were treated with nirmatrelvir-ritonavir (NMV-r). We found that NMV-r was associated with greater incidence of viral rebound compared to no treatment. For those that did not rebound, NMV-r significantly reduced time to PCR conversion.

Publisher

Cold Spring Harbor Laboratory

Reference18 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

2. Najjar-Debbiny R , Gronich N , Weber G , et al. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis 2022.

3. Press release: Pfizer announced additional Phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death 2021. URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results#.YuqqMD0XAEc.link. Accessed 03 August 2022.

4. Li H , Gao M , You H , et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19. Clin Infect Dis 2022.

5. COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2;Biosafety and Health;2023-10

2. Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19;Journal of Advanced Research;2023-10

3. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody;2023-09-17

4. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19;Expert Review of Anti-infective Therapy;2023-08-01

5. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis;Reviews in Medical Virology;2023-07-23